Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

[1]  J. Shatzel,et al.  Syndromes of Thrombotic Microangiopathy. , 2017, The Medical clinics of North America.

[2]  R. Torra,et al.  Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento: Documento de consenso , 2015 .

[3]  G. Ardissino,et al.  Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  J. Pu,et al.  Successful discontinuation of eculizumab therapy in a patient with aHUS , 2014, Annals of Hematology.

[5]  V. D’Agati,et al.  Phenotypic expansion of DGKE-associated diseases. , 2014, Journal of the American Society of Nephrology : JASN.

[6]  A. Jankauskienė,et al.  Macrovascular involvement in a child with atypical hemolytic uremic syndrome , 2014, Pediatric Nephrology.

[7]  Ikuyo Yamaguchi,et al.  Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease , 2014, Pediatric Nephrology.

[8]  G. Keating.  Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome , 2013, Drugs.

[9]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[10]  S. Cataland,et al.  Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation , 2013, Annals of Hematology.

[11]  P. Chowdhury,et al.  The use of eculizumab in renal transplantation , 2013, Clinical transplantation.

[12]  L. Rostaing,et al.  Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[13]  John Hwa,et al.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.

[14]  N. Kamar,et al.  Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  E. Baskın,et al.  Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab , 2013, Pediatric Nephrology.

[16]  G. Ardissino,et al.  Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  V. Frémeaux-Bacchi,et al.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.

[18]  B. Acar,et al.  Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation , 2012, Pediatric Nephrology.

[19]  R. Montgomery,et al.  Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[20]  P. Theofilou.  Quality of Life in Patients Undergoing Hemodialysis or Peritoneal Dialysis Treatment , 2011, Journal of clinical medicine research.

[21]  G. Remuzzi,et al.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[22]  A. Garnier,et al.  Plasmatherapy in atypical hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.

[23]  P. Zipfel,et al.  Thrombotic microangiopathies: new insights and new challenges , 2010, Current opinion in nephrology and hypertension.

[24]  K. Amann,et al.  Thrombotic microangiopathy: new insights , 2010, Current opinion in nephrology and hypertension.

[25]  D. Geary,et al.  Platelet-associated complement factor H in healthy persons and patients with atypical HUS. , 2009, Blood.

[26]  B. Hurault de Ligny,et al.  Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  D. Lambrechts,et al.  Thrombomodulin mutations in atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[28]  G. Ariceta,et al.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome , 2009, Pediatric Nephrology.

[29]  G. Remuzzi,et al.  Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. , 2009, The American journal of pathology.

[30]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[31]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[32]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[33]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[34]  G. Remuzzi,et al.  ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.

[35]  Yoshihiro Kokubo,et al.  FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.

[36]  R. Browne,et al.  Validation of the Center for Medicare and Medicaid Services algorithm for eligibility for dialysis , 2004, Pediatric Nephrology.

[37]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  S. D. Subba Rao,et al.  Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.

[39]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[40]  L. Matis,et al.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.

[41]  S. Rodríguez de Córdoba,et al.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[42]  Richard J. H. Smith,et al.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.

[43]  D. Solís.  US Food and Drug Administration , 2010 .

[44]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.